Lyell Immunopharma (LYEL)
(Delayed Data from NSDQ)
$10.98 USD
-0.34 (-3.00%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $10.85 -0.13 (-1.18%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LYEL 10.98 -0.34(-3.00%)
Will LYEL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LYEL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LYEL
Lyell Immunopharma (LYEL) Upgraded to Strong Buy: Here's Why
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
LYEL: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a Turnaround
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should Know
Other News for LYEL
12 Health Care Stocks Moving In Thursday's After-Market Session
Lyell Immunopharma (LYEL) Secures $100M Private Placement to Fund Clinical Milestones | LYEL ...
Lyell Immunopharma announces up to $100 million equity private placement
Lyell Immunopharma Announces up to $100 Million Equity Private Placement | LYEL Stock News
Lyell Immunopharma announces up to $100M equity private placement